Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515424 · ClinicalTrials.gov registry record · Phase 1
Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension
A Phase 1 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT00515424 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 90 participants.
The verdict
NCT00515424, a Phase 1 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.
Interventions
- DRUG RKI983
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515424
The ClinicalTrials.gov registry entry for NCT00515424 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RKI983 is the first listed.
NCT00515424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515424 about?
NCT00515424 is a clinical study titled "Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension". This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.
What is the current status of trial NCT00515424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2007-07.
What interventions are being tested in trial NCT00515424?
The interventions under investigation include: RKI983 (DRUG).
Who is sponsoring clinical trial NCT00515424?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.